Eurofins Technologies Announces Launch of RT PCR kIts for Rapid Detection of SARS-CoV-2 Variant B.1.1529
26 Novembre 2021 - 05:48PM
Business Wire
Regulatory News:
Eurofins Technologies (Paris:ERF) continues to innovate and
develop a wide range of diagnostic solutions for COVID-19,
particularly in response to the threat of emerging mutations.
Researchers have identified a new SARS-CoV-2 variant with a
concerningly high number of mutations in the spike protein. The
variant, first identified in Botswana in November 2021, is
spreading rapidly across South Africa.
The variant contains more than 30 mutations to the spike protein
— the SARS-CoV-2 protein that recognises host cells and is the main
target of the body’s natural or vaccine induced immune responses.
Similar mutations found in variants such as Delta and Alpha have
been linked to heightened infection rates and potential resistance
to infection-blocking antibodies [1]. However, the combination of
these mutations seems to be unique to this variant. No related
variants have so far been identified [2].
It is critical to quickly identify clusters to limit spread of
this variant. Eurofins, through Gold Standard Diagnostics Europe,
provides the toolset to rapidly identify the variant B.1.1.529. GSD
NovaType Select is a set of RT-PCR assays to specifically detect
mutations in the genome of SARS-CoV-2 in around 1 hour, much faster
than genome sequencing methods.
GSD NovaType Select P681H can differentiate variant B.1.1.529
from the currently dominant Delta variant and can be used as a
large-scale screening test for PCR positive samples. Additionally,
all samples positive for the mutation P681H should be tested using
GSD NovaType Select T478K and K417N to further differentiate
B.1.1.529 from other circulating SARS-CoV-2 variants of concern
[3].
Gilles Martin, Eurofins CEO said: “I am very pleased with the
speed at which we have brought to market a new test for the
detection of this variant. We have maintained significant testing
capacity across our markets, which together with innovations such
as this, positions us very well to help deliver highly accurate,
variant-detecting COVID tests at significant scale, to help
navigate the pandemic.”
References:
[1]
https://www.nature.com/articles/d41586-021-03552-w
[2]
https://www.youtube.com/watch?v=Vh4XMueP1zQ&t=709s
[3]
https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
For more information, please visit
www.eurofins-technologies.com
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of
900 laboratories in over 50 countries, Eurofins’ companies offer a
portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211126005549/en/
Investor Relations Eurofins Scientific Gabriel JULIA Phone: +32
2 766 1620 E-mail: ir@eurofins.com
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024